Related Experiment Videos
Microvascular decompression.
W Jeffrey Elias1, Kim J Burchiel
1Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97201-3098, USA.
The Clinical Journal of Pain
|January 23, 2002
Summary
Microvascular decompression (MVD) is the only trigeminal neuralgia treatment addressing pathogenesis, offering long-lasting pain relief. Early MVD is advocated to prevent refractory symptoms, aided by high-resolution MRI for candidate selection.
Area of Science:
- Neurosurgery
- Neurology
- Medical Imaging
Background:
- Microvascular decompression (MVD) is the sole treatment for trigeminal neuralgia (TN) targeting its presumed cause.
- MVD provides durable pain relief and preserves facial sensation.
- Untreated TN may progress to atypical, treatment-refractory features, indicating ongoing neuropathic injury.
Purpose of the Study:
- To advocate for early MVD in trigeminal neuralgia treatment.
- To improve patient selection for MVD using advanced imaging techniques.
Main Methods:
- Incorporation of high-resolution magnetic resonance imaging (MRI) into the preoperative algorithm.
- Utilizing MRI to accurately define neurovascular relationships at the trigeminal nerve complex.
Main Results:
- High-resolution MRI demonstrates high accuracy in identifying neurovascular compression.
- Early MVD is proposed as a strategy to prevent disease progression and refractory symptoms.
Conclusions:
- Early microvascular decompression is recommended for trigeminal neuralgia when performed with low morbidity rates.
- High-resolution MRI enhances the selection of appropriate candidates for MVD, optimizing treatment outcomes.